COSM
Cosmos Health Inc.
COSM offers stronger modeled upside, but that advantage does not outweigh its weaker overall profile.
OSCR
Oscar Health, Inc.
OSCR has the edge over COSM overall, supported by stronger fundamentals and lower modeled downside.
COSM Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Weak | |
| Weak |
COSM's revenue is currently healthy, but its profitability, cash flow and balance sheet are under pressure.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
COSM PE Valuation
COSM has no meaningful PE right now: it lost money over the past year. If it returns to profit as analysts expect, today's price would be 2.1x next year's earnings.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
COSM Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect COSM to return to profit, with revenue growing. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
COSM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.10 | — |
| Q2 2026 | -$0.66 | +$0.38 |
| Q1 2026 | -$0.66 | +$0.43 |
| Q4 2025 | -$0.63 | +$0.54 |
| Q3 2025 | -$0.76 | +$1.70 |
| Q2 2025 | -$1.04 | +$1.24 |
| Q1 2025 | -$1.09 | +$1.13 |
| Q4 2024 | -$1.17 | +$0.98 |
| Q3 2021 | -$11.50 | -454% |
COSM is still losing money, but far less than before: $0.66 per share over the past year, against $25.00 at its worst in late 2019.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over COSM on earnings quality, reporting a profit while its opponent remains loss making.
COSM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $19M | +29% |
| Q1 2026 | $17.9M | +31% |
| Q4 2025 | $19.7M | +39% |
| Q3 2025 | $17.1M | +38% |
| Q2 2025 | $14.7M | +12% |
| Q1 2025 | $13.7M | -6% |
| Q4 2024 | $14.2M | -10% |
| Q3 2024 | $12.4M | -3.2% |
COSM's revenue has grown year over year for five quarters in a row: $19M last quarter, up 29% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -15% | +2.5 points |
| Q1 2026 | -12% | -6.1 points |
| Q4 2025 | -58% | +5.1 points |
| Q3 2025 | -11% | +7.4 points |
| Q2 2025 | -18% | +1 points |
| Q1 2025 | -6.1% | +6.5 points |
| Q4 2024 | -63% | +23 points |
| Q3 2024 | -18% | +5.5 points |
COSM's operating margin was −15% last quarter, up 2.5 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over COSM on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over COSM on profitability, with a higher operating margin.
COSM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$1.8M | -$549.4K |
| Q1 2026 | -$1.1M | -$879.6K |
| Q4 2025 | -$4.6M | -$697.9K |
| Q3 2025 | -$2.5M | -583% |
| Q2 2025 | -$1.2M | +$12.6K |
| Q1 2025 | -$198.8K | +$3.3M |
| Q4 2024 | -$3.9M | -532% |
| Q3 2024 | $511K | +$5.1M |
COSM has burned cash in almost every quarter: −$10M over the past year, against −$5M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over COSM on cash generation, producing positive trailing cash flow while its opponent burns cash.
COSM Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2021 | 8.5x | High |
| Q4 2020 | 3.3x | Elevated |
| Q3 2020 | -0.3x | Net Cash |
| Q2 2020 | -1.1x | Net Cash |
| Q1 2020 | -1.9x | Net Cash |
| Q4 2019 | 0.6x | Very low |
COSM's net debt is about 8.5 years of its operating earnings (EBITDA), after holding more cash than debt a year ago.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
COSM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 40.5 | Neutral |
| Stochastic | 31.7 | Neutral |
COSM's weekly RSI is 41 (neutral) and its Stochastic is 32 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
COSM PE vs Healthcare Sector
| Metric | COSM | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
COSM has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
COSM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.31 | 32% below |
| 20 week MA | $0.27 | 22% below |
| 50 week MA | $0.33 | 36% below |
| 100 week MA | $0.49 | 57% below |
| 200 week MA | $1.10 | 81% below |
COSM is in a downtrend: it's below all five of its weekly moving averages, and 81% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over COSM on trend strength, trading above more of its moving averages.
COSM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $62.5 | $127.5 | +104% |
| 2021 | $127.5 | $99.0 | -22% |
| 2022 | $99.0 | $6.40 | -94% |
| 2023 | $6.40 | $1.41 | -78% |
| 2024 | $1.41 | $0.68 | -52% |
| 2025 | $0.68 | $0.51 | -25% |
| 2026 YTD | $0.51 | $0.21 | -59% |
COSM has finished five years in a row lower, and it's down 59% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over COSM on returns for 2026, with the stronger performance.